Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Anika Therapeutics (ANIK) over the last 16 years, with Q2 2025 value amounting to $50.2 million.

  • Anika Therapeutics' Accumulated Depreciation & Amortization changed N/A to $50.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $50.2 million, marking a year-over-year change of. This contributed to the annual value of $46.3 million for FY2024, which is 522.2% up from last year.
  • Per Anika Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $50.2 million for Q2 2025.
  • In the past 5 years, Anika Therapeutics' Accumulated Depreciation & Amortization registered a high of $50.2 million during Q2 2025, and its lowest value of $39.6 million during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $46.2 million (2022), whereas its average is $45.6 million.
  • As far as peak fluctuations go, Anika Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 1667.38% in 2022, and later crashed by 475.5% in 2023.
  • Anika Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $39.6 million in 2021, then grew by 16.67% to $46.2 million in 2022, then fell by 4.75% to $44.0 million in 2023, then grew by 5.22% to $46.3 million in 2024, then increased by 8.39% to $50.2 million in 2025.
  • Its last three reported values are $50.2 million in Q2 2025, $47.6 million for Q1 2025, and $46.3 million during Q4 2024.